# A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

> **NCT03070301** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** LEE011
- **DRUG:** everolimus

## Key facts

- **NCT ID:** NCT03070301
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-27
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-10-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03070301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03070301, "A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03070301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*